BIO/Stakeholder letter to the Senate Judiciary Committee in opposition to the “Pride in Patent Ownership Act” (S. 2774)

Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…